To investigate, through a systematic review, the effects of the use of highly diluted drugs in the treatment of experimental infection with Trypanosoma cruzi.
Design:
The authors searched for scientific publications in the databases PubMed, Web of Science, SCOPUS, LILACS, and the Google Scholar search system, from 2000 to 2018, following the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement. According to the criteria established, a total of 22 studies were included.
Settings/Location:
The study took place at the State University of Maringá, Maringá, PR, Brazil.
Subjects:
Male mice (Mus musculus) or rats (Rattus norvegicus).
Interventions:
Highly diluted drugs.
Outcome measures:
The parameters evaluated in the studies were parasitological, clinical, immunological, histopathological and hematological.
Results:
The studies demonstrated that the effects of highly diluted drugs are related to their dynamizations, treatment regimen, and host susceptibility to T. cruzi infection, and depend on the initial information transmitted to the treated organism, making this information the “model” of how the treated organism will react. Regardless of the mechanism of action, these drugs provide a decrease in inflammation, which is one of the central phenomena of the pathogenesis of T. cruzi infection.
Conclusions:
This systematic review brings out the importance of the T. cruzi infection model as a reliable and valid model for studying different effects produced by highly diluted drugs. Considering the findings and in a broader perspective, this study contributes to considering these drugs as a possible way of dealing with “treatment” in general, presents the need to reexamine the biochemical model and develop a model for the effect of high dilutions in general, as well as for the treatment of parasitic infections.
Get full access to this article
View all access options for this article.
References
1.
Ministério de Saúde. Epidemiological Bulletin. Acute wounds in Brazil: Historical series from 2000 to 2013 [Boletim Epidemiológico. Chagas aguda no Brasil: série histórica de 2000 a 2013]. Secretaria de Vigilância em saúde, 2015; 46:1–9.
2.
Ministério da Saúde. Health Surveillance Guide. Chagas Disease [Guia de Vigilância Em Saúde. Doença de Chagas], 2016.
3.
Oliveira M deF, Nagao-DiasAT, PontesVMO de, et al.Etiological treatment of Chagas disease in Brazil [Tratamento Etiológico Da Doença De Chagas No Brasil]. Revpatoltrop, 2008; 37:209–228.
4.
VeigaF, FerrazFN, AleixoDL, et al.Use of biotherapics in experimental Trypanosoma cruzi infection: Bibliographic review.[Uso de Bioterápicos Na Infecção Experimental Por Trypanosoma Cruzi: Revisão Bibliográfica]. Rev UNINGÁ Rev, 2014; 18:05–11.
5.
Villano BonaminL. The soundness of basic homeopathy research [A solidez da pesquisa básica em homeopatia]. Leoni Villano Bonamin, 2017; 80:89–97.
6.
Brasil. Brazilian Homeopathic Pharmacopoeia [Farmacopeia Homeopática Brasileira]. Brasilia, 2011.
7.
TeixeiraMZ. Homeopathy: Supporting Medical Practice [Homeopatia: prática médica coadjuvante]. Rev Ass Méd Bras, 2007; 53:374–376.
8.
AleixoDL, BenvenuttiM, LeraK, et al.The association of ponderal benznidazole with its ultra-high diluted formula reduces the toxic effects and allows increasing of dose in dose-dependent protocol in mice infected with Trypanosoma cruzi. Int J High Dil Res, 2015; 14:10–19.
9.
PedalinoCMV. Homeopathic medicines in power chords [Medicamentos homeopáticos em acordes de potência]. Cult homeopat, 2006; 16:18–20.
10.
AleixoDL, FerrazFN, Ferreira ÉC, et al. Highly diluted medication reduces parasitemia and improves experimental infection evolution by Trypanosoma cruzi. BMC Res Notes, 2012; 5:352.
11.
BellerEM, GlasziouPP, AltmanDG, et al.PRISMA for abstracts: Reporting systematic reviews in journal and conference abstracts. PLoS Med, 2013; 10:e1001419.
12.
ShamseerL, MoherD, ClarkeM, et al.Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation. BMJ, 2015; 349:g7647.
13.
AlmeidaL, CamposM, HerreraH, et al.Effects of homeopathy in mice experimentally infected with Trypanosoma cruzi. Homeopathy, 2008; 97:65–69.
14.
QueirozAO, XavierSCC, FariaKG, et al.Evaluation of Trypanosoma cruzi 30DH biotherapeutic: An in vivo study [Avaliação do Bioterápico Trypanosoma cruzi 30DH: Um Estudo In Vivo]. Cult Homeopat, 2007; 96:175–182.
15.
Falkowski-TemporiniGJ, LopesCR, MassiniPF, et al.Homeopathic drug association promotes parasitemia reduction and clinical improvement in Trypanosoma cruzi infected mice [Associação de medicamentos homeopáticos promove diminuição da parasitemia e melhora clínica em camundongos infectados por Trypanosoma cruzi]. VITTALLE—Rev Cien Saud, 2018; 30:36–45.
16.
Brustolin AleixoCF, FerrazFN, MassiniPF, et al.Beneficial immunomodulatory and neuro digestive effect in Trypanosoma cruzi infection after Lycopodium clavatum 13c treatment. Microb Pathog, 2017; 112:1–4.
17.
Falkowski-TemporiniGJ, LopesCRC, MassiniPF, et al.Increased of the hepatocytes and splenocytes apoptosis accompanies clinical improvement and higher survival in mice infected with Trypanosoma cruzi and treated with highly diluted Lycopodium clavatum. Microb Pathog, 2017; 110:107–116.
18.
FerreiraEC, CiupaL, PortocarreroAR, et al.Phosphorus protects cardiac tissue by modifying the immune response in rats infected by Trypanosoma cruzi. Cytokine, 2017; 102:102–106.
19.
PortocarreroAR, SandriP, FerrazF, et al.Effect of dynamized ethyl alcohol in mice infected with Trypanosoma cruzi: Can this dynamized substance really be considered inert to infected animals?. Braz J Surg Clin Res, 2017; 20:7–11.
20.
AleixoDL, FerrazFN, CiupaL, et al.Randomized study using biotherapeutic “T. cruzi 3dH” impairs experimental infection by Trypanosoma cruzi. J Exp Integr Med, 2015; 5:100–104.
21.
FerrazFN, da VeigaFK, AleixoDL, et al.Different treatment schemes and dynamizations of Trypanosoma cruzi biotherapies: What information do they transfer to the organism in infected mice?. Homeopathy, 2016; 105:327–337.
22.
FerrazFN, da VeigaFK, AleixoDL, et al.Biotherapies of rabbit serum modulate the immune response and decrease parasite load in mice infected with Trypanosoma cruzi. J Appl Biomed, 2016; 14:187–197.
23.
PupulinART, BrachtL, de Oliveira DalalioMM, et al.Canova medication changes TNF-α and IL-10 serum levels in mice infected with Trypanosoma cruzi Y strain. Asian Pac J Trop Med, 2016; 9:860–865.
24.
PupulinART, Marques-AraujoS, ToledoMJO, et al.Canova medication modifies parasitological parameters in mice infected with Trypanosoma cruzi. Exp Parasitol, 2010; 126:435–440.
25.
AleixoDL, FerrazFN, de MeloCS, et al.Changes of RAPD profile of Trypanosoma cruzi II with Canova and Benznidazole. Homeopathy, 2008; 97:59–64.
26.
FerrazFN, SimoniGK, do NascimentoA, et al.Different forms of administration of biotherapy 7dH in mice experimentally infected by Trypanosoma cruzi produce different effects. Homeopathy, 2011; 100:237–243.
27.
FerrazFN, BilottiCC, AleixoDL, et al.Hematological and parasitological changes in mice experimentally infected by Trypanosoma cruzi and treated with biotherapy 7dH. Eur J Integr Med, 2014; 6:664–671.
28.
Araújo-JorgeTC de, CastroSL de. Chagas Disease: Manual for Animal Experimentation [Doença de Chagas: Manual Para Experimentação Animal], Rio de Janeiro: Fiocruz, 2013.
29.
Falkowski-TemporiniGJ, LopesCR, MassiniPF, et al.Predominance of Th1 response, increase of megakaryocytes and Kupffer cells are related to survival in Trypanosoma cruzi infected mice treated with Lycopodium clavatum. Cytokine, 2016; 88:57–61.
30.
LopesCR, FalkowskiGJ, BrustolinCF, et al.Highly diluted medication reduces tissue parasitism and inflammation in mice infected by Trypanosoma cruzi. Homeopathy, 2015; 14:186–193.
31.
HahnemannS. Organon da Arte de Curar. São Paulo: GEHSP “Benoit Mure,” 2013, DOI: 10.1590/S0080-623420140000600026.
32.
SandriPF, PortocarreroAR, CiupaL, et al.Dynamized ethyl alcohol improves immune response and behavior in murine infection with Trypanosoma cruzi. Cytokine, 2017; 99:240–248.
33.
PavanelliR. Citocinas e Óxido Nítrico Na Doença de Chagas [Cytokines and Nitric Oxide in Chagas Disease]. Biosaúde, 2008; 10:146–147.
34.
BonaminLV. Signal and Images, Contributions and Contradictions about High Dilution Research. Netherlands: Springer, 2008.
35.
BasombríoMA, BesuschioS. Trypanosoma cruzi culture used as vaccine to prevent chronic Chagas' disease in mice. Infect Immun, 1982; 36:351–356.
36.
SepulvedaP, HontebeyrieM, LiegeardP, et al.DNA-based immunization with Trypanosoma cruzi complement regulatory protein elicits complement lytic antibodies and confers protection against Trypanosoma cruzi infection. Infect Immun, 2000; 68:4986–4991.
37.
SandriP, AleixoDL, Sanchez FalkowskiGJ, et al.Trypanosoma cruzi: Biotherapy made from trypomastigote modulates the inflammatory response. Homeopathy, 2015; 104:48–56.
38.
WickramasingheSN, AbdallaSH. Blood and bone marrow changes in malaria. Best Pract Res Clin Haematol, 2000; 13:277–299.
39.
FerrazFNF, da VeigaFKF, AleixoDDL, et al.Modulation of IFN-γ, IL-4 and IL-17 cytokines is related to parasitemia control in mice infected by Trypanosoma cruzi and treated with biotherapy. OnLine J Biol Sci, 2015; 15:251–259.
40.
GabrielM, Ciupa LDLA, et al. Different treatment schemes with Canova Medication® modify differently the course of mice infection by Trypanosoma cruzi. J Complement Med Alt Healthcare, 2017; 4:555632.
41.
FicheraLE, AlbaredaMC, LaucellaSA, et al.Intracellular growth of Trypanosoma cruzi in cardiac myocytes is inhibited by cytokine-induced nitric oxide release. Infect Immun, 2004; 72:3 59–63.
42.
AlibertiJC, SoutoJT, MarinoAP, et al.Modulation of chemokine production and inflammatory responses in interferon-gamma- and tumor necrosis factor-R1-deficient mice during Trypanosoma cruzi infection. Am J Pathol, 2001; 158:1433–1440.
43.
SilvaJS, VespaGN, CardosoMA, et al.Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages. Infect Immun, 1995; 63:4862–4867.
44.
Lages-SilvaE, FilardiLS, BrenerZ. Effect of the host specific treatment in the phagocytosis of Trypanosoma cruzi blood forms by mouse peritoneal macrophages. Mem Inst Oswaldo Cruz, 1990; 85:401–405.
45.
FerrazML, GazzinelliRT, AlvesRO, et al.Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of Posaconazole and Benznidazole in treatment of experimental acute Trypanosoma cruzi infection. Antimicrob Agents Chemother, 2009; 53:174–179.
46.
Carlos Pinto DiasJ, Novaes RamosA, DiasGontijo, et al.II Brazilian Consensus on Chagas Disease, 2015 [II Consenso Brasileiro em Doença de Chagas, 2015]. Epidemiol Serv Saúde, 2016; 25:1–10.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
